Vir Biotechnology announces a Gilead cancer collaboration with US$90 million upfront and contingent milestones for three ...
Upstart stock is trading at a price-to-sales (P/S) ratio of just 2, which is a steep discount to its three-year average of 5.4. It might be a great buy right now because it's already cheap, but if a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results